{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:33:59Z","timestamp":1793885639628,"version":"4.8.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020132","name":"TUD Dresden University of Technology Faculty of Medicine Carl Gustav Carus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008658","name":"German Cancer Research Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008658","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012353","name":"German Cancer Consortium","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012353","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.esmoop.2025.104532","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T20:25:08Z","timestamp":1743798308000},"page":"104532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comprehensive genomic and transcriptomic analysis enables molecularly guided therapy options in peritoneal and pleural mesothelioma"],"prefix":"10.1016","volume":"10","author":[{"given":"L.","family":"M\u00f6hrmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ole\u015b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Knol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Mundt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Paramasivam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fr\u00f6hlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Hutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"H\u00fcllein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Jahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Scheffold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.E.","family":"M\u00f6hrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Hanf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kreutzfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.E.","family":"Heilig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-V.","family":"Teleanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.B.","family":"Lipka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Baude-M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Jelas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.T.","family":"Rieke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.V.","family":"Klotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Boerries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.L.","family":"Illert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Allg\u00e4uer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Stenzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.A.","family":"Kerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Horak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Heining","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Schr\u00f6ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"H\u00fcbschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fr\u00f6hling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Glimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.esmoop.2025.104532_bib1","first-page":"293","article-title":"Peritoneal mesothelioma","volume":"24","author":"Raptopoulos","year":"1985","journal-title":"Crit Rev Diagn Imaging"},{"issue":"4","key":"10.1016\/j.esmoop.2025.104532_bib2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1179\/oeh.2007.13.4.398","article-title":"Incidence and descriptive epidemiology of mesothelioma in the United States, 1999-2002","volume":"13","author":"Larson","year":"2007","journal-title":"Int J Occup Environ Health"},{"issue":"6","key":"10.1016\/j.esmoop.2025.104532_bib3","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s10552-009-9328-9","article-title":"Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973-2005","volume":"20","author":"Moolgavkar","year":"2009","journal-title":"Cancer Causes Control"},{"issue":"7","key":"10.1016\/j.esmoop.2025.104532_bib4","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S1470-2045(13)70257-2","article-title":"Asbestos is not just asbestos: an unrecognised health hazard","volume":"14","author":"Baumann","year":"2013","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.104532_bib5","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.ajpath.2013.07.029","article-title":"Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-\u03b1 signaling","volume":"183","author":"Qi","year":"2013","journal-title":"Am J Pathol"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2025.104532_bib6","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.21037\/tlcr.2019.11.11","article-title":"Epidemiology of mesothelioma in the 21st century in Europe and the United States, 40 years after restricted\/banned asbestos use","volume":"9","author":"Alpert","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.esmoop.2025.104532_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103821","article-title":"Global magnitude and temporal trend of mesothelioma burden along with the contribution of occupational asbestos exposure in 204 countries and territories from 1990 to 2019: results from the Global Burden of Disease Study 2019","volume":"179","author":"Han","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.104532_bib8","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.esmoop.2025.104532_bib9","series-title":"Thoracic Tumours","year":"2021"},{"issue":"11","key":"10.1016\/j.esmoop.2025.104532_bib10","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/JTO.0b013e31826915f1","article-title":"Initial analysis of the international association for the study of lung cancer mesothelioma database","volume":"7","author":"Rusch","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.104532_bib11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"33","author":"Popat","year":"2022","journal-title":"Ann Oncol"},{"issue":"10272","key":"10.1016\/j.esmoop.2025.104532_bib12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104532_bib13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejso.2020.02.011","article-title":"Peritoneal mesothelioma: PSOGI\/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"47","author":"Kusamura","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.104532_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.19934","article-title":"Clinical efficacy of immune checkpoint inhibitors in patients with advanced malignant peritoneal mesothelioma","volume":"4","author":"Raghav","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104532_bib15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/CCO.0000000000000697","article-title":"Malignant pleural mesothelioma: recent developments","volume":"33","author":"Sinn","year":"2021","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.104532_bib16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00420-003-0498-6","article-title":"Factors influencing long-term survival in mesothelioma patients? Results of the German mesothelioma register","volume":"77","author":"Neumann","year":"2004","journal-title":"Int Arch Occup Environ Health"},{"issue":"suppl 3","key":"10.1016\/j.esmoop.2025.104532_bib17","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2021.39.3_suppl.460","article-title":"Comparison of clinical characteristics and survival outcomes in patients with malignant peritoneal and pleural mesothelioma","volume":"39","author":"Katiyar","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.104532_bib18","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","article-title":"Genomic landscape of pleural and peritoneal mesothelioma tumours","volume":"127","author":"Hiltbrunner","year":"2022","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2025.104532_bib19","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jtho.2021.09.012","article-title":"Molecular characterization of peritoneal mesotheliomas","volume":"17","author":"Offin","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2025.104532_bib20","article-title":"Molecular characterization of mesothelioma: impact of histologic type and site of origin on molecular landscape","volume":"6","author":"Dagogo-Jack","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.104532_bib21","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104532_bib22","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13073-022-01060-8","article-title":"Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma","volume":"14","author":"Creaney","year":"2022","journal-title":"Genome Med"},{"issue":"4","key":"10.1016\/j.esmoop.2025.104532_bib23","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41588-023-01321-1","article-title":"Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity","volume":"55","author":"Mangiante","year":"2023","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.esmoop.2025.104532_bib24","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2213-2600(20)30390-8","article-title":"Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial","volume":"9","author":"Fennell","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.esmoop.2025.104532_bib25","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S1470-2045(22)00062-6","article-title":"Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial","volume":"23","author":"Fennell","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2025.104532_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00171","article-title":"Validating comprehensive next-generation sequencing results for precision oncology: the NCT\/DKTK molecularly aided stratification for tumor eradication research experience","volume":"2","author":"Lier","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.104532_bib27","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1158\/2159-8290.CD-21-0126","article-title":"Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers","volume":"11","author":"Horak","year":"2021","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.esmoop.2025.104532_bib28","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1002\/ijc.32358","article-title":"Variant classification in precision oncology","volume":"145","author":"Leichsenring","year":"2019","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104532_bib29","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41698-023-00458-w","article-title":"NCT\/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology","volume":"7","author":"Mock","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.esmoop.2025.104532_bib30","article-title":"National center for tumor diseases precision oncology thesaurus for drugs: a curated database for drugs, drug classes, and drug targets in precision cancer medicine","volume":"7","author":"Kreutzfeldt","year":"2023","journal-title":"JCO Clin Cancer Inform"},{"issue":"33","key":"10.1016\/j.esmoop.2025.104532_bib31","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1200\/JCO.2009.26.5983","article-title":"Pilot study using molecular profiling of patients\u2019 tumors to find potential targets and select treatments for their refractory cancers","volume":"28","author":"Von Hoff","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.104532_bib32","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.annonc.2022.07.008","article-title":"Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers","volume":"33","author":"Jahn","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.104532_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100612","article-title":"Genomic landscape and molecularly informed therapy in thymic carcinoma and other advanced thymic epithelial tumors","author":"M\u00f6hrmann","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.esmoop.2025.104532_bib48","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","article-title":"Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat Res"},{"issue":"7463","key":"10.1016\/j.esmoop.2025.104532_bib36","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.esmoop.2025.104532_bib49","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/ijc.30828","article-title":"Precision oncology based on omics data: the NCT Heidelberg experience","volume":"141","author":"Horak","year":"2017","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2025.104532_bib37","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.esmoop.2025.104532_bib38","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41591-019-0424-4","article-title":"Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial","volume":"25","author":"Rodon","year":"2019","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.esmoop.2025.104532_bib39","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s43018-024-00754-9","article-title":"Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers","volume":"5","author":"Chapeau","year":"2024","journal-title":"Nat Cancer"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.104532_bib40","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.2022.40.16_suppl.3003","article-title":"First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation","volume":"40","author":"Dumbrava","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.104532_bib41","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cell.2018.03.039","article-title":"Pathogenic germline variants in 10,389 adult cancers","volume":"173","author":"Huang","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.esmoop.2025.104532_bib42","article-title":"New pathogenic germline variants identified in mesothelioma","volume":"179","author":"Belcaid","year":"2023","journal-title":"Lung Cancer Amst Neth"},{"issue":"28","key":"10.1016\/j.esmoop.2025.104532_bib43","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","article-title":"Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma","volume":"36","author":"Panou","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.104532_bib44","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.27351","article-title":"Germline variants incidentally detected via tumor-only genomic profiling of patients with mesothelioma","volume":"6","author":"Mitchell","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.esmoop.2025.104532_bib45","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/gcc.22670","article-title":"Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes","volume":"57","author":"Betti","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2025.104532_bib46","article-title":"Phase 2 study of olaparib in malignant mesothelioma and correlation of efficacy with germline or somatic mutations in BAP1 gene","volume":"2","author":"Ghafoor","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.esmoop.2025.104532_bib51","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1038\/s41467-022-31866-4","article-title":"Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity","volume":"13","author":"M\u00f6hrmann","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2025.104532_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000669","article-title":"How I treat malignant pleural mesothelioma","volume":"4","author":"Viscardi","year":"2019","journal-title":"ESMO Open"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925004016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925004016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T23:58:02Z","timestamp":1745539082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925004016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2059702925004016"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.104532","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive genomic and transcriptomic analysis enables molecularly guided therapy options in peritoneal and pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.104532","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"104532"}}